المؤلفون: Bagia S., Chua Y.J., Pavlakis N., Goldstein D., Aghmesheh M., Joubert W., Grimes D., Harris M., Burge M., Samra J.S., Haghighi K.S., Truskett P., Simes J., Jaber M., Gananadha S., O'Rourke N., Bryant R., Nathanson L., Cavallucci D., Barbour A., Fawcett J., O'Rourke T., Croagh D., Jones R., Chan H., Gebski V.J., Croagh D.G., Kench J.G., Hicks R., Coates A., Gurney H., Do V., Marschner I., Mitchell J., Donoghoe M., Goldstone S., Yip S., Barbour A.P., Donoghoe M.W., Harris M.T.

مصطلحات الفهرس: wound dehiscence, wound infection, alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], CA 19-9 antigen/ec [Endogenous Compound], capecitabine/cb [Drug Combination], capecitabine/dt [Drug Therapy], carcinoembryonic antigen/ec [Endogenous Compound], fluorodeoxyglucose, fluorouracil/cb [Drug Combination], fluorouracil/dt [Drug Therapy], gemcitabine/ae [Adverse Drug Reaction], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], paclitaxel/ae [Adverse Drug Reaction], abdominal infection, adult, aged, anastomosis leakage, anemia/si [Side Effect], anorexia/si [Side Effect], article, cancer combination chemotherapy, cancer radiotherapy, cancer survival, cholangitis/si [Side Effect], clinical article, clinical assessment, diarrhea/si [Side Effect], drug dose reduction, drug efficacy, drug safety, drug withdrawal, dyspnea/si [Side Effect], edema/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, flu like syndrome/si [Side Effect], gastrointestinal disease/si [Side Effect], hand foot syndrome/si [Side Effect], human, infection/si [Side Effect], male, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neoadjuvant chemotherapy, neutrophil count, overall survival, pancreas adenocarcinoma/dt [Drug Therapy], pancreas adenocarcinoma/rt [Radiotherapy], pancreas adenocarcinoma/su [Surgery], perioperative period, phase 2 clinical trial, platelet count, positron emission tomography-computed tomography, postoperative complication, postoperative hemorrhage, preoperative chemotherapy, progression free survival, prospective study, side effect/si [Side Effect], stomach paresis, treatment response, vomiting/si [Side Effect], wound complication, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28868
Annals of Surgical Oncology
Click here for full text options
LibKey Link

المؤلفون: Markman B., Raghunath A., Chandrasekara S.D., Anthony S.N.

مصطلحات الفهرس: chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/pc [Prevention], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], disease severity, drug use, fatigue/si [Side Effect], headache/si [Side Effect], human, meta analysis, review, systematic review, treatment duration, treatment response, dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], granisetron/cb [Drug Combination], granisetron/dt [Drug Therapy], irinotecan/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], advanced cancer/dt [Drug Therapy], adverse event, anorexia/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29167
Critical Reviews in Oncology/Hematology
Click here for full text options
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

المؤلفون: Bagia S., Chua Y.J., Pavlakis N., Goldstein D., Aghmesheh M., Joubert W., Grimes D., Harris M., Burge M., Samra J.S., Haghighi K.S., Truskett P., Simes J., Jaber M., Gananadha S., O'Rourke N., Bryant R., Nathanson L., Cavallucci D., Barbour A., Fawcett J., O'Rourke T., Croagh D., Jones R., Chan H., Gebski V.J., Croagh D.G., Kench J.G., Hicks R., Coates A., Gurney H., Do V., Marschner I., Mitchell J., Donoghoe M., Goldstone S., Yip S., Barbour A.P., Donoghoe M.W., Harris M.T.

مصطلحات الفهرس: wound dehiscence, wound infection, alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], CA 19-9 antigen/ec [Endogenous Compound], capecitabine/cb [Drug Combination], capecitabine/dt [Drug Therapy], carcinoembryonic antigen/ec [Endogenous Compound], fluorodeoxyglucose, fluorouracil/cb [Drug Combination], fluorouracil/dt [Drug Therapy], gemcitabine/ae [Adverse Drug Reaction], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], paclitaxel/ae [Adverse Drug Reaction], abdominal infection, adult, aged, anastomosis leakage, anemia/si [Side Effect], anorexia/si [Side Effect], article, cancer combination chemotherapy, cancer radiotherapy, cancer survival, cholangitis/si [Side Effect], clinical article, clinical assessment, diarrhea/si [Side Effect], drug dose reduction, drug efficacy, drug safety, drug withdrawal, dyspnea/si [Side Effect], edema/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, flu like syndrome/si [Side Effect], gastrointestinal disease/si [Side Effect], hand foot syndrome/si [Side Effect], human, infection/si [Side Effect], male, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neoadjuvant chemotherapy, neutrophil count, overall survival, pancreas adenocarcinoma/dt [Drug Therapy], pancreas adenocarcinoma/rt [Radiotherapy], pancreas adenocarcinoma/su [Surgery], perioperative period, phase 2 clinical trial, platelet count, positron emission tomography-computed tomography, postoperative complication, postoperative hemorrhage, preoperative chemotherapy, progression free survival, prospective study, side effect/si [Side Effect], stomach paresis, treatment response, vomiting/si [Side Effect], wound complication, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28868
Annals of Surgical Oncology
LibKey Link

المؤلفون: Markman B., Raghunath A., Chandrasekara S.D., Anthony S.N.

مصطلحات الفهرس: chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/pc [Prevention], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], disease severity, drug use, fatigue/si [Side Effect], headache/si [Side Effect], human, meta analysis, review, systematic review, treatment duration, treatment response, dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], granisetron/cb [Drug Combination], granisetron/dt [Drug Therapy], irinotecan/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], advanced cancer/dt [Drug Therapy], adverse event, anorexia/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29167
Critical Reviews in Oncology/Hematology
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
LibKey Link

المؤلفون: Alamgeer M., Lum C.

مصطلحات الفهرس: drug efficacy, drug potentiation, encephalitis/si [Side Effect], fatigue/si [Side Effect], genetic heterogeneity, genomics, hand foot syndrome/si [Side Effect], hedgehog signaling, human, hypertension/si [Side Effect], liquid biopsy, monotherapy, mutational load, nonhuman, Notch signaling, overall survival, pneumonia/si [Side Effect], progression free survival, review, small cell lung cancer/dt [Drug Therapy], small cell lung cancer/rt [Radiotherapy], solid malignant neoplasm/dt [Drug Therapy], adavosertib/ct [Clinical Trial], adavosertib/cb [Drug Combination], adavosertib/dt [Drug Therapy], alisertib/ct [Clinical Trial], alisertib/cb [Drug Combination], alisertib/cm [Drug Comparison], alisertib/dt [Drug Therapy], anlotinib/ae [Adverse Drug Reaction], anlotinib/ct [Clinical Trial], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cediranib/ct [Clinical Trial], cediranib/cb [Drug Combination], cediranib/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cixutumumab/cb [Drug Combination], cixutumumab/dt [Drug Therapy], crlx101/ct [Clinical Trial], crlx101/cb [Drug Combination], crlx101/dt [Drug Therapy], durvalumab/ct [Clinical Trial], durvalumab/cb [Drug Combination], durvalumab/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/cm [Drug Comparison], ipilimumab/dt [Drug Therapy], lurbinectedin/ae [Adverse Drug Reaction], lurbinectedin/ct [Clinical Trial], lurbinectedin/dt [Drug Therapy], lurbinectedin/tm [Unexpected Outcome of Drug Treatment], niraparib/ct [Clinical Trial], niraparib/cb [Drug Combination], niraparib/cm [Drug Comparison], niraparib/dt [Drug Therapy], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/cb [Drug Combination], nivolumab/cm [Drug Comparison], nivolumab/dt [Drug Therapy], olaparib/ae [Adverse Drug Reaction], olaparib/ct [Clinical Trial], olaparib/cb [Drug Combination], olaparib/cm [Drug Comparison], olaparib/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], placebo, prexasertib/ct [Clinical Trial], prexasertib/cb [Drug Combination], prexasertib/dt [Drug Therapy], rovalpituzumab tesirine/ct [Clinical Trial], rovalpituzumab tesirine/cb [Drug Combination], rovalpituzumab tesirine/cm [Drug Comparison], rovalpituzumab tesirine/dt [Drug Therapy], rucaparib/ct [Clinical Trial], rucaparib/cb [Drug Combination], rucaparib/dt [Drug Therapy], sonidegib/ct [Clinical Trial], sonidegib/cb [Drug Combination], sonidegib/dt [Drug Therapy], sonidegib/tm [Unexpected Outcome of Drug Treatment], taladegib/ct [Clinical Trial], taladegib/cb [Drug Combination], taladegib/dt [Drug Therapy], talazoparib/dt [Drug Therapy], talazoparib/tm [Unexpected Outcome of Drug Treatment], temozolomide/ae [Adverse Drug Reaction], temozolomide/ct [Clinical Trial], temozolomide/cb [Drug Combination], temozolomide/dt [Drug Therapy], topotecan/ct [Clinical Trial], topotecan/cm [Drug Comparison], topotecan/dt [Drug Therapy], unindexed drug, veliparib/ae [Adverse Drug Reaction], veliparib/ct [Clinical Trial], veliparib/cb [Drug Combination], veliparib/cm [Drug Comparison], veliparib/dt [Drug Therapy], vismodegib/dt [Drug Therapy], vismodegib/cb [Drug Combination], anlotinib/cm [Drug Comparison], anlotinib/dt [Drug Therapy], bevacizumab/ct [Clinical Trial], bevacizumab/cb [Drug Combination], bevacizumab/dt [Drug Therapy], adoptive immunotherapy, anorexia/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cancer immunotherapy, cancer resistance, circulating tumor cell, DNA damage response, drug dose escalation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35889
Cancers
Click here for full text options
LibKey Link

المؤلفون: Lee M., Croagh D., Holt D.Q., Fox A., Wong R., Moore G.T., Freckelton J.

مصطلحات الفهرس: neutropenia/si [Side Effect], observational study, pancreas adenocarcinoma/dt [Drug Therapy], retrospective study, sarcopenia/si [Side Effect], skeletal muscle, gemcitabine/ae [Adverse Drug Reaction], gemcitabine/cb [Drug Combination], gemcitabine/do [Drug Dose], gemcitabine/dt [Drug Therapy], gemcitabine/pv [Special Situation for Pharmacovigilance], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/cb [Drug Combination], paclitaxel/do [Drug Dose], paclitaxel/dt [Drug Therapy], paclitaxel/pv [Special Situation for Pharmacovigilance], skeletal muscle area, major clinical study, adult, aged, anorexia/si [Side Effect], article, body composition, body surface, cancer combination chemotherapy, cancer patient, computer assisted tomography, cross-sectional study, demography, diarrhea/si [Side Effect], drug dose reduction, electronic medical record, female, human, infection/si [Side Effect], male, musculoskeletal system parameters, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35668
Nutrition and Cancer
Click here for full text options
LibKey Link

المؤلفون: Alamgeer M., Lum C.

مصطلحات الفهرس: drug efficacy, drug potentiation, encephalitis/si [Side Effect], fatigue/si [Side Effect], genetic heterogeneity, genomics, hand foot syndrome/si [Side Effect], hedgehog signaling, human, hypertension/si [Side Effect], liquid biopsy, monotherapy, mutational load, nonhuman, Notch signaling, overall survival, pneumonia/si [Side Effect], progression free survival, review, small cell lung cancer/dt [Drug Therapy], small cell lung cancer/rt [Radiotherapy], solid malignant neoplasm/dt [Drug Therapy], adavosertib/ct [Clinical Trial], adavosertib/cb [Drug Combination], adavosertib/dt [Drug Therapy], alisertib/ct [Clinical Trial], alisertib/cb [Drug Combination], alisertib/cm [Drug Comparison], alisertib/dt [Drug Therapy], anlotinib/ae [Adverse Drug Reaction], anlotinib/ct [Clinical Trial], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cediranib/ct [Clinical Trial], cediranib/cb [Drug Combination], cediranib/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cixutumumab/cb [Drug Combination], cixutumumab/dt [Drug Therapy], crlx101/ct [Clinical Trial], crlx101/cb [Drug Combination], crlx101/dt [Drug Therapy], durvalumab/ct [Clinical Trial], durvalumab/cb [Drug Combination], durvalumab/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/cm [Drug Comparison], ipilimumab/dt [Drug Therapy], lurbinectedin/ae [Adverse Drug Reaction], lurbinectedin/ct [Clinical Trial], lurbinectedin/dt [Drug Therapy], lurbinectedin/tm [Unexpected Outcome of Drug Treatment], niraparib/ct [Clinical Trial], niraparib/cb [Drug Combination], niraparib/cm [Drug Comparison], niraparib/dt [Drug Therapy], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/cb [Drug Combination], nivolumab/cm [Drug Comparison], nivolumab/dt [Drug Therapy], olaparib/ae [Adverse Drug Reaction], olaparib/ct [Clinical Trial], olaparib/cb [Drug Combination], olaparib/cm [Drug Comparison], olaparib/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], placebo, prexasertib/ct [Clinical Trial], prexasertib/cb [Drug Combination], prexasertib/dt [Drug Therapy], rovalpituzumab tesirine/ct [Clinical Trial], rovalpituzumab tesirine/cb [Drug Combination], rovalpituzumab tesirine/cm [Drug Comparison], rovalpituzumab tesirine/dt [Drug Therapy], rucaparib/ct [Clinical Trial], rucaparib/cb [Drug Combination], rucaparib/dt [Drug Therapy], sonidegib/ct [Clinical Trial], sonidegib/cb [Drug Combination], sonidegib/dt [Drug Therapy], sonidegib/tm [Unexpected Outcome of Drug Treatment], taladegib/ct [Clinical Trial], taladegib/cb [Drug Combination], taladegib/dt [Drug Therapy], talazoparib/dt [Drug Therapy], talazoparib/tm [Unexpected Outcome of Drug Treatment], temozolomide/ae [Adverse Drug Reaction], temozolomide/ct [Clinical Trial], temozolomide/cb [Drug Combination], temozolomide/dt [Drug Therapy], topotecan/ct [Clinical Trial], topotecan/cm [Drug Comparison], topotecan/dt [Drug Therapy], unindexed drug, veliparib/ae [Adverse Drug Reaction], veliparib/ct [Clinical Trial], veliparib/cb [Drug Combination], veliparib/cm [Drug Comparison], veliparib/dt [Drug Therapy], vismodegib/dt [Drug Therapy], vismodegib/cb [Drug Combination], anlotinib/cm [Drug Comparison], anlotinib/dt [Drug Therapy], bevacizumab/ct [Clinical Trial], bevacizumab/cb [Drug Combination], bevacizumab/dt [Drug Therapy], adoptive immunotherapy, anorexia/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cancer immunotherapy, cancer resistance, circulating tumor cell, DNA damage response, drug dose escalation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35889
Cancers
LibKey Link

المؤلفون: Lee M., Croagh D., Holt D.Q., Fox A., Wong R., Moore G.T., Freckelton J.

مصطلحات الفهرس: neutropenia/si [Side Effect], observational study, pancreas adenocarcinoma/dt [Drug Therapy], retrospective study, sarcopenia/si [Side Effect], skeletal muscle, gemcitabine/ae [Adverse Drug Reaction], gemcitabine/cb [Drug Combination], gemcitabine/do [Drug Dose], gemcitabine/dt [Drug Therapy], gemcitabine/pv [Special Situation for Pharmacovigilance], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/cb [Drug Combination], paclitaxel/do [Drug Dose], paclitaxel/dt [Drug Therapy], paclitaxel/pv [Special Situation for Pharmacovigilance], skeletal muscle area, major clinical study, adult, aged, anorexia/si [Side Effect], article, body composition, body surface, cancer combination chemotherapy, cancer patient, computer assisted tomography, cross-sectional study, demography, diarrhea/si [Side Effect], drug dose reduction, electronic medical record, female, human, infection/si [Side Effect], male, musculoskeletal system parameters, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35668
Nutrition and Cancer
LibKey Link